[go: up one dir, main page]

AR003430A1 - Una composicion farmaceutica para inhibir el crecimiento de canceres - Google Patents

Una composicion farmaceutica para inhibir el crecimiento de canceres

Info

Publication number
AR003430A1
AR003430A1 ARP960103044A AR10304496A AR003430A1 AR 003430 A1 AR003430 A1 AR 003430A1 AR P960103044 A ARP960103044 A AR P960103044A AR 10304496 A AR10304496 A AR 10304496A AR 003430 A1 AR003430 A1 AR 003430A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
cancers
inhibit
growth
salts
Prior art date
Application number
ARP960103044A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR003430A1 publication Critical patent/AR003430A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica para tratar cánceres, tumores, virus, caracterizado porque comprende una cantidad segura y eficaz del compuesto defórmula (I), donde R1 es optativamente un alquilo, cicloalquilo (por ej. ciclopentilo ócic lohexilo), arilo o haloarilo (por ej., fenilo o 2,4-diclorofenilo) o aralquilo (por ej. bencilo)sustituido; y sales y complejos de metales o éteres de ellos, y sales con agregado de ácido farmacéuticamente aceptables,no tóxicas con ácidosorgánicos e inorgánicos.
ARP960103044A 1995-06-07 1996-07-06 Una composicion farmaceutica para inhibir el crecimiento de canceres AR003430A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/473,818 US5665751A (en) 1995-06-07 1995-06-07 Pharmaceutical composition for inhibiting the growth of cancers

Publications (1)

Publication Number Publication Date
AR003430A1 true AR003430A1 (es) 1998-08-05

Family

ID=23881116

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103044A AR003430A1 (es) 1995-06-07 1996-07-06 Una composicion farmaceutica para inhibir el crecimiento de canceres

Country Status (20)

Country Link
US (3) US5665751A (es)
EP (1) EP0831815A1 (es)
JP (1) JPH11506733A (es)
KR (1) KR19990022618A (es)
CN (1) CN1259867A (es)
AR (1) AR003430A1 (es)
AU (1) AU717201B2 (es)
BR (1) BR9609093A (es)
CA (1) CA2223803A1 (es)
CZ (1) CZ391897A3 (es)
HU (1) HUP9802629A3 (es)
IL (1) IL118426A (es)
NO (1) NO975661L (es)
NZ (1) NZ308393A (es)
PL (1) PL324078A1 (es)
SK (1) SK168797A3 (es)
TR (2) TR199701535T1 (es)
TW (1) TW466113B (es)
WO (1) WO1996040120A1 (es)
ZA (1) ZA964377B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100396278B1 (ko) * 1994-03-21 2003-11-28 톰슨 존 브라운 피부질환의치료및피부의살균용겔
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) * 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
JPH11510187A (ja) * 1995-08-04 1999-09-07 ザ プロクター アンド ギャンブル カンパニー 癌の成長を阻害するためのフルコナゾールの使用
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
RU2163804C1 (ru) * 2000-06-01 2001-03-10 Торрент Фармасьютикалс Лимитед Способ получения флуконазола
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) * 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) * 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6515074B2 (en) * 2001-01-22 2003-02-04 Delphi Technologies, Inc. Thermoplastic polymer alloy compositions and process for manufacture thereof
CN100334084C (zh) * 2005-04-26 2007-08-29 武汉大学 联三唑化合物及其制备方法和用途
CN100451007C (zh) * 2006-10-12 2009-01-14 杭州宇龙化工有限公司 含芳醚双三氮唑类化合物及其用途
WO2008079973A2 (en) 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
US8278415B2 (en) 2006-12-21 2012-10-02 Centocor, Inc. Dimeric high affinity EGFR constructs and uses thereof
US8834920B2 (en) 2006-12-21 2014-09-16 Alza Corporation Liposome composition for targeting egfr receptor
KR100980328B1 (ko) * 2007-12-14 2010-09-06 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는트리아졸릴-티오-에타논 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암 예방 및 치료용조성물
CN102321036A (zh) * 2011-07-13 2012-01-18 王健祥 一种氟康唑可溶性盐的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079062A (en) * 1974-11-18 1978-03-14 Janssen Pharmaceutica N.V. Triazole derivatives
US4160838A (en) * 1977-06-02 1979-07-10 Janssen Pharmaceutica N.V. Antimicrobial and plant-growth-regulating triazole derivatives
GB2078719B (en) * 1980-06-02 1984-04-26 Ici Ltd Heterocyclic compounds
EP0069442B1 (en) * 1981-06-06 1985-02-20 Pfizer Limited Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them
DE3837463A1 (de) * 1988-11-04 1990-05-10 Bayer Ag Substituierte bisazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
US5360612A (en) * 1992-10-13 1994-11-01 Pfizer Inc. Pharmaceutical compositions containing triazole derivatives for rectal administration

Also Published As

Publication number Publication date
TW466113B (en) 2001-12-01
CA2223803A1 (en) 1996-12-19
WO1996040120A1 (en) 1996-12-19
US5840742A (en) 1998-11-24
HUP9802629A3 (en) 2000-01-28
TR200102287T2 (tr) 2002-06-21
NO975661L (no) 1998-02-09
IL118426A0 (en) 1996-09-12
AU717201B2 (en) 2000-03-23
TR199701535T1 (xx) 1998-03-21
US5665751A (en) 1997-09-09
IL118426A (en) 2001-03-19
ZA964377B (en) 1997-02-17
BR9609093A (pt) 1999-06-29
NZ308393A (en) 2001-04-27
HUP9802629A2 (hu) 1999-04-28
AU5802196A (en) 1996-12-30
EP0831815A1 (en) 1998-04-01
USRE37003E (en) 2000-12-26
PL324078A1 (en) 1998-05-11
KR19990022618A (ko) 1999-03-25
CN1259867A (zh) 2000-07-12
NO975661D0 (no) 1997-12-05
CZ391897A3 (cs) 1998-05-13
JPH11506733A (ja) 1999-06-15
SK168797A3 (en) 1998-12-02

Similar Documents

Publication Publication Date Title
AR003430A1 (es) Una composicion farmaceutica para inhibir el crecimiento de canceres
IT1264451B1 (it) 3-(carbossimetossifenil)-benzofuran-2-oni come agenti stabilizzanti
IT1264452B1 (it) 3- (acilossifenil) benzofuran-2-oni come agenti stabilizzanti
ES2063093T3 (es) Composiciones orales.
ES2107557T3 (es) Derivado de acido hidroxamico a base de sulfonamida aromatica.
ES2090400T3 (es) Agentes para preservar materiales tecnicos del ataque por insectos.
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
BR9604974A (pt) Composição farmacêutica contendo benzimidazol para inibir o crescimento de canceres
ES2041794T3 (es) Composicion aromatica vinilica estabilizada.
RU94044454A (ru) Ингибитор аутоимунных заболеваний
FR2751879B1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
IS2387B (is) Æxliseyðandi efni
ES2062215T3 (es) Derivados aminoalcoxibencenicos sustituidos.
YU46998B (sh) Postupak za dobijanje derivata cefema i medjuproizvoda za iste
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
FI923664A0 (fi) Piperidinderivat.
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
RU94044357A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования увеличения веса, индуцирования снижения веса или ингибирования аппетита
ES2102772T3 (es) Compuesto citotoxico y antiviral.
ES8203848A1 (es) Procedimiento para preparar derivados de acido acetico
ATE23148T1 (de) Antivirus alpha-alpha-dialkyl adamantylethylamine.
ES8707497A1 (es) Un procedimiento para preparar derivados de azetidinona
ATE353639T1 (de) In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb
ES2090781T3 (es) Agentes de n-aminoalquilcarboniloxialquilpirrol contra insectos, acaros y moluscos.
AR024082A1 (es) Sales antitranspirantes y metodos para su preparacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure